Here we show that in colon cancer cells, despite identical downstream SMAD signaling, activin and TGFβ have opposing effects on the cdk2 inhibitor p21 resulting in distinct regulations of each pathway. The gene discussed is TGFB1; the disease is malignant colon neoplasm.